> Home
 
  > About
 
  > Portfolio
 
  > News
 
  > Documents for download
 
  > Investors
 
  > Press Room
 
  > Policies and Ethics
 
  > Contact
 
  > Links


Karolinska Development
AB (publ)
org. nr. 556707-5048
Registered office: Solna
© Karolinska Development 2008

 

 

Axelar AB

Axelar AB is a Swedish biotechnology company that focuses its activities on research related to the insulin-like growth factor-1 (IGF-1) receptor inhibitors and their applications in important human diseases, especially cancer.

Contact
Johan Harmenberg, CEO
  +46 8 524 865 99
 
  www.axelar.se

 

 

  
 

Actar AB
Akinion Pharmaceuticals AB
Aprea AB
Athera Biotechnologies AB
Avaris AB
Axelar AB
BioArctic Neuroscience AB
BioChromix Pharma AB
Biocis Pharma Ltd.
Bioneris AB
BioResonator AB
Biosergen A/S
Clanotech AB
Cytoguide
DermaGen AB
Dilafor AB
Eribis Pharmaceuticals AB
HBV Theranostica AB
IMED AB
Independent Pharmaceutica AB
InDex Pharmaceuticals AB
Inhalation Sciences Sweden AB
Lipopeptide AB
NeoDynamics AB
NephroGenex Inc.
NeuroTherapeutics AB
NovaSAID AB
Omnio Healer AB
Oncopeptides AB
Pergamum AB
PharmaSurgics AB
Promimic AB
ProNoxis AB
Umecrine AB
Umecrine Cognition AB
Umecrine Mood AB
XSpray Microparticles AB